[go: up one dir, main page]

FR2897535B1 - SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS - Google Patents

SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS

Info

Publication number
FR2897535B1
FR2897535B1 FR0601577A FR0601577A FR2897535B1 FR 2897535 B1 FR2897535 B1 FR 2897535B1 FR 0601577 A FR0601577 A FR 0601577A FR 0601577 A FR0601577 A FR 0601577A FR 2897535 B1 FR2897535 B1 FR 2897535B1
Authority
FR
France
Prior art keywords
aminotetrodrafuran
butyrolactones
prototypic
alkylaminoalkyl
alkylamines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0601577A
Other languages
French (fr)
Other versions
FR2897535A1 (en
Inventor
Alexandre Vamvakides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0601577A priority Critical patent/FR2897535B1/en
Publication of FR2897535A1 publication Critical patent/FR2897535A1/en
Application granted granted Critical
Publication of FR2897535B1 publication Critical patent/FR2897535B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0601577A 2006-02-21 2006-02-21 SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS Expired - Fee Related FR2897535B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0601577A FR2897535B1 (en) 2006-02-21 2006-02-21 SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0601577A FR2897535B1 (en) 2006-02-21 2006-02-21 SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS

Publications (2)

Publication Number Publication Date
FR2897535A1 FR2897535A1 (en) 2007-08-24
FR2897535B1 true FR2897535B1 (en) 2012-07-20

Family

ID=37452158

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0601577A Expired - Fee Related FR2897535B1 (en) 2006-02-21 2006-02-21 SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS

Country Status (1)

Country Link
FR (1) FR2897535B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1005865B (en) * 2007-01-17 2008-04-07 Anavex Life Sciences Corp. NEW SIGMA LIGANDS with anti-apoptotic and/or pro-apoptotic action on the cells biochemical mechanisms and neuroprotective, anti-cancer, anti-metastatic, and anti-chronic inflammatory properties.
GR1006794B (en) * 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης The new sigma(σ)-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action.
GR1007686B (en) * 2011-07-08 2012-09-12 Αλεξανδρος Δημητριου Βαμβακιδης Synthesis of (+)- and (-)-1-(5,5-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethylamine, (+)-and (-)-1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethylamine and (+)- and (-)-1-(2,2-diphenyltetrahydrofuran-3-yl)-n-methylmethylamine
US10507196B2 (en) 2016-01-26 2019-12-17 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (en) * 1996-02-21 1997-02-20 Synthesis and method of synthesis of a molecular (AE 37) of anticonvulsant, antidepressant and neuroleptic tropic action.

Also Published As

Publication number Publication date
FR2897535A1 (en) 2007-08-24

Similar Documents

Publication Publication Date Title
EP2124905A4 (en) VEGETARIAN MICROCAPSULES
DK2069335T3 (en) PYRIDIN-3-YLD DERIVATIVES AS IMMUNO MODULATORS
CL2008000789A1 (en) COMPOUNDS DERIVED FROM ADENINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS, USEFUL TO TREAT ALLERGIC, VIRAL OR CANCER DISEASES, AMONG OTHERS.
DK2069336T3 (en) PYRIDIN-4-YL DERIVATIVES AS IMMUNO MODULATORS
DK2291368T3 (en) Substituted gamma-lactam as a therapeutic agent
DK1928845T3 (en) Aminodiazepines as toll-like receptor modulators
EP3827865C0 (en) MASK SYSTEM
DE602007007534D1 (en) Hydraulic modulator for braking devices
DK2682093T3 (en) packaging system
EP2376098A4 (en) MEDICINAL AGENTS RELATED BY DIPEPTIDES
UY33124A (en) AGENTS AND EPITHES LINKED TO WISE
HUE036377T2 (en) Pharmaceutical preparations containing sigma receptor ligands
DK1871181T3 (en) Supplements for HIV patients
ATE527244T1 (en) N-(1,1,1,3,3,3-HEXAFLUORINE-2-HYDROXYPROPANE-2-YL)BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS
DE602007001944D1 (en) braking system
IT1394102B1 (en) WEIGHT PER WHEEL.
BR112013033938A2 (en) signaling a label-switched path tunneling (lsp) model
DK2252609T3 (en) PYRIDIN-2-YL DERIVATIVES AS IMMUNO MODULATORS
DK2373652T3 (en) SUBSTITUTED PIPERIDIN-SPIRO-PYRROLIDINON AND PIPERIDINON COMPOUNDS USED AS H3 MODULATORS
BRPI0920341A2 (en) pneumatic brake cylinder.
EA200900958A1 (en) DRUG NEVIRAPIN PREPARATION
DE602006011753D1 (en) SIGMA-DELTA MODULATORS
FR2897535B1 (en) SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS
FI20065800A0 (en) Polyvalent bioconjugates
DE602008003432D1 (en) SUBSTITUTED FUROÄ2,3-BÜPYRIDIN DERIVATIVES AS CANNABINOID-1-RECEPTOR MODULATORS

Legal Events

Date Code Title Description
CA Change of address

Effective date: 20120312

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

ST Notification of lapse

Effective date: 20191006